Active, Not Recruiting
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice - CA209-234
Updated: 22 September, 2022 | ClinicalTrials.gov
Gender(s)
Age Range
Active, Not Recruiting
Inclusion Criteria: - Age ≥18 - Histologically or cytologically confirmed diagnosis of melanoma (including uveal melanoma) or lung cancer - Treatment with commercial nivolumab for the first time, alone or in combination with ipilimumab, for the approved indications of nivolumab within 14 days before informed consent for this study OR in the case where treatment has not yet been initiated, documentation that the treatment strategy is determined before an informed consent to study participation, and treatment is initiated within 28 days after informed consent Exclusion Criteria: - Prior participation in a clinical trial within the past 4 weeks - Previously treated with anti-PD-1, anti-PD-L1, or anti-PD-L2 antibodies - Previously treated with anti-CTLA-4 for lung cancer - Current or pending participation in a clinical trial - Current or pending systemic treatment for cancer other than melanoma and lung cancer - Inability to comply with the study protocol
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
